OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis $0.38 -0.02 (-5.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.38▼$0.4050-Day Range$0.37▼$0.5052-Week Range$0.36▼$1.09Volume1.03 million shsAverage Volume1.73 million shsMarket Capitalization$469.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Northwest Biotherapeutics alerts: Email Address Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Northwest Biotherapeutics Stock (OTCMKTS:NWBO)Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Read More NWBO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NWBO Stock News HeadlinesJuly 3, 2024 | prnewswire.comNorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth OpportunitiesJune 17, 2024 | prnewswire.comNorthwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual PropertyJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.May 25, 2024 | nasdaq.comNorthwest Biotherapeutics Inc (NWBO) Dividend HistoryMarch 21, 2024 | prnewswire.comNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of DirectorsMarch 2, 2024 | ft.com‘Spoofing’ case might draw back curtain on high-speed trading firmsFebruary 29, 2024 | uk.finance.yahoo.comNorthwest Biotherapeutics, Inc. (NWBO)February 23, 2024 | benzinga.comNorthwest Biotherapeutics Stock (OTC:NWBO), Short Interest ReportJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.February 7, 2024 | finance.yahoo.comNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory CertificationDecember 22, 2023 | msn.comNorthwest Biotherapeutics submits marketing application to UK MHRA for DCVax-LDecember 21, 2023 | finanznachrichten.deNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For GlioblastomaDecember 21, 2023 | finance.yahoo.comNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For GlioblastomaNovember 22, 2023 | finance.yahoo.comNorthwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization ApplicationOctober 31, 2023 | morningstar.comNorthwest Biotherapeutics Inc NWBOOctober 14, 2023 | msn.comNorthwest Bio: Another Small Filing DelayOctober 13, 2023 | seekingalpha.comNW Bio dips on announcing delay in submission of marketing application for DCVaxOctober 13, 2023 | marketwatch.comNorthwest Biotherapeutics Shares Slide on Application DelaySee More Headlines Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CUSIPN/A CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,600,000.00 Net Margins-5,258.91% Pretax Margin-5,258.91% Return on EquityN/A Return on Assets-241.52% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$1.93 million Price / Sales242.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-6.33Miscellaneous Outstanding Shares1,230,455,000Free Float1,123,405,000Market Cap$467.57 million OptionableNot Optionable Beta-0.57 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Linda F. Powers J.D. (Age 68)Chairperson, CEO, President, CFO & Chief Accounting Officer Comp: $1.1MDr. Alton L. Boynton Ph.D. (Age 79)Founder, Chief Scientific Officer, Secretary & Director Comp: $450kDr. Marnix L. Bosch M.B.A. (Age 65)Ph.D., Chief Technical Officer Comp: $597.5kMr. Leslie J. Goldman (Age 79)Senior VP & General Counsel Comp: $825kMr. David InnesVice President of Investor RelationsKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSAVerona PharmaNASDAQ:VRNANewAmsterdam PharmaNASDAQ:NAMSEvotecNASDAQ:EVOKura OncologyNASDAQ:KURAView All Competitors NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed this year? Northwest Biotherapeutics' stock was trading at $0.7010 on January 1st, 2024. Since then, NWBO stock has decreased by 45.8% and is now trading at $0.38. View the best growth stocks for 2024 here. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) released its earnings results on Friday, May, 10th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The biotechnology company earned $0.28 million during the quarter. How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA) and This page (OTCMKTS:NWBO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Northwest Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NWBO Stock Alerts